Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BCAL Diagnostics Limited ( (AU:BDX) ) has provided an update.
BCAL Diagnostics Limited has announced the expansion of its BREASTEST plus blood test to three additional specialist breast clinics in Sydney and Melbourne, starting mid-May 2025. This expansion aligns with BCAL’s national rollout strategy to improve early breast cancer detection in women with high breast density, a group where traditional mammography often faces challenges. The move is a significant milestone in BCAL’s efforts to provide more women with access to this breakthrough diagnostic tool, enhancing early and accurate diagnosis and potentially improving health outcomes.
More about BCAL Diagnostics Limited
BCAL Diagnostics is an Australian and US-based biotechnology company focused on advancing early and accurate breast cancer detection. The company offers innovative, non-invasive blood tests, such as BREASTEST plus, which complement existing breast screening methods by providing additional lipidomic insights to rule out breast cancer. BCAL aims to improve screening accuracy and reduce the need for further investigation and biopsy, ultimately enhancing health outcomes for women.
YTD Price Performance: -22.00%
Average Trading Volume: 294,946
Technical Sentiment Signal: Buy
Current Market Cap: A$28.55M
For detailed information about BDX stock, go to TipRanks’ Stock Analysis page.